Advocacy intelligence hub — real-time data for patient organizations
NYMALIZE: FDA approved
Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Nymalize
Azurity
NYMALIZE
(nimodipine)Orphan drugArbor Pharmaceuticals, Inc.
Dihydropyridine Calcium Channel Blocker [EPC]
12.1 Mechanism of Action Nimodipine is a dihydropyridine calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon ...
Browse all Acquired aneurysmal subarachnoid hemorrhage news →
View all Acquired aneurysmal subarachnoid hemorrhage specialists →